NAMACIZUMAB

A FIRST-IN-CLASS, ONLY-IN-CLASS NEGATIVE ALLOSTERIC MODULATING ANTIBODY TO THE CANNABINOID RECEPTOR 1

Overview

As part of our mission to utilize technology to make an impact on healthcare, our second therapeutic antibody (namacizumab) is being developed to address fibrotic and metabolic disease, including the emerging epidemic – nonalcoholic steatohepatitis (NASH). NASH is very rapidly becoming the largest contributor to liver failure and the need for liver transplant.

NASH is a potentially fatal condition for which there are currently no approved treatments. The cannabinoid receptor 1 (CB1) is a well-validated target for NASH. Namacizumab is the only known negative allosteric modulating antibody (NAMA)  to CB1. We believe it will provide a differentiated approach for the treatment of NASH as well as other fibrotic and metabolic diseases.

Indications

Nonalcoholic steatohepatitis (NASH), fibrotic and metabolic diseases.

Phase of Development

Namacizumab has completed IND-enabling studies and has submitted for approval to initiate a Phase 1a/1b clinical trial.